JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 645.03 Billion KRW | 2.72% |
| 2022 | 627.97 Billion KRW | -0.8% |
| 2021 | 633.05 Billion KRW | 15.29% |
| 2020 | 549.08 Billion KRW | -4.21% |
| 2019 | 573.2 Billion KRW | -3.47% |
| 2018 | 593.79 Billion KRW | -5.88% |
| 2017 | 630.87 Billion KRW | -3.1% |
| 2016 | 651.07 Billion KRW | 6.13% |
| 2015 | 613.48 Billion KRW | 3.26% |
| 2014 | 594.11 Billion KRW | 0.81% |
| 2013 | 589.36 Billion KRW | -2.28% |
| 2012 | 603.14 Billion KRW | -9.59% |
| 2011 | 667.09 Billion KRW | 25.48% |
| 2010 | 531.63 Billion KRW | 6.7% |
| 2009 | 498.23 Billion KRW | 18.69% |
| 2008 | 419.78 Billion KRW | 37.97% |
| 2007 | 304.25 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 657.44 Billion KRW | 1.92% |
| 2024 Q2 | 663.89 Billion KRW | 0.98% |
| 2023 Q1 | 671.08 Billion KRW | 6.87% |
| 2023 Q2 | 647.76 Billion KRW | -3.48% |
| 2023 FY | 645.03 Billion KRW | 2.72% |
| 2023 Q3 | 667.18 Billion KRW | 3.0% |
| 2023 Q4 | 645.03 Billion KRW | -3.32% |
| 2022 Q4 | 627.97 Billion KRW | 0.64% |
| 2022 Q2 | 624.26 Billion KRW | -1.82% |
| 2022 Q3 | 623.98 Billion KRW | -0.05% |
| 2022 Q1 | 635.85 Billion KRW | 0.44% |
| 2022 FY | 627.97 Billion KRW | -0.8% |
| 2021 Q3 | 591.31 Billion KRW | 1.3% |
| 2021 FY | 633.05 Billion KRW | 15.29% |
| 2021 Q1 | 534.23 Billion KRW | -2.7% |
| 2021 Q4 | 633.05 Billion KRW | 7.06% |
| 2021 Q2 | 583.69 Billion KRW | 9.26% |
| 2020 Q2 | 575.85 Billion KRW | 0.86% |
| 2020 Q1 | 570.94 Billion KRW | -0.39% |
| 2020 Q3 | 560.48 Billion KRW | -2.67% |
| 2020 Q4 | 549.08 Billion KRW | -2.03% |
| 2020 FY | 549.08 Billion KRW | -4.21% |
| 2019 Q2 | 601.22 Billion KRW | -1.2% |
| 2019 Q1 | 608.52 Billion KRW | 2.48% |
| 2019 FY | 573.2 Billion KRW | -3.47% |
| 2019 Q3 | 582.9 Billion KRW | -3.05% |
| 2019 Q4 | 573.2 Billion KRW | -1.66% |
| 2018 Q3 | 618.88 Billion KRW | -0.37% |
| 2018 Q2 | 621.2 Billion KRW | -5.99% |
| 2018 Q1 | 660.78 Billion KRW | 4.74% |
| 2018 FY | 593.79 Billion KRW | -5.88% |
| 2018 Q4 | 593.79 Billion KRW | -4.05% |
| 2017 Q3 | 638.13 Billion KRW | 1.24% |
| 2017 Q2 | 630.31 Billion KRW | -0.43% |
| 2017 Q1 | 633.04 Billion KRW | -2.77% |
| 2017 Q4 | 630.87 Billion KRW | -1.14% |
| 2017 FY | 630.87 Billion KRW | -3.1% |
| 2016 FY | 651.07 Billion KRW | 6.13% |
| 2016 Q1 | 616.71 Billion KRW | 0.53% |
| 2016 Q2 | 610.51 Billion KRW | -1.01% |
| 2016 Q3 | 635.76 Billion KRW | 4.14% |
| 2016 Q4 | 651.07 Billion KRW | 2.41% |
| 2015 Q2 | 611.77 Billion KRW | -2.92% |
| 2015 Q1 | 630.16 Billion KRW | 6.07% |
| 2015 Q4 | 613.48 Billion KRW | -1.85% |
| 2015 Q3 | 625.04 Billion KRW | 2.17% |
| 2015 FY | 613.48 Billion KRW | 3.26% |
| 2014 Q2 | 607.98 Billion KRW | -0.74% |
| 2014 Q1 | 612.53 Billion KRW | 3.93% |
| 2014 Q3 | 613.93 Billion KRW | 0.98% |
| 2014 Q4 | 594.11 Billion KRW | -3.23% |
| 2014 FY | 594.11 Billion KRW | 0.81% |
| 2013 FY | 589.36 Billion KRW | -2.28% |
| 2013 Q4 | 589.36 Billion KRW | -2.22% |
| 2013 Q3 | 602.76 Billion KRW | 0.36% |
| 2013 Q2 | 600.6 Billion KRW | -4.88% |
| 2013 Q1 | 631.41 Billion KRW | 4.69% |
| 2012 Q1 | 672.37 Billion KRW | 0.0% |
| 2012 FY | 603.14 Billion KRW | -9.59% |
| 2012 Q4 | 603.14 Billion KRW | 0.0% |
| 2011 FY | 667.09 Billion KRW | 25.48% |
| 2011 Q3 | 653.47 Billion KRW | 2.64% |
| 2011 Q1 | 662.54 Billion KRW | 24.63% |
| 2011 Q2 | 636.65 Billion KRW | -3.91% |
| 2010 Q1 | 552.73 Billion KRW | 10.94% |
| 2010 Q2 | 567.73 Billion KRW | 2.71% |
| 2010 FY | 531.63 Billion KRW | 6.7% |
| 2010 Q4 | 531.63 Billion KRW | -5.08% |
| 2010 Q3 | 560.07 Billion KRW | -1.35% |
| 2009 Q1 | 482.94 Billion KRW | 15.05% |
| 2009 Q4 | 498.23 Billion KRW | -3.44% |
| 2009 Q3 | 515.99 Billion KRW | 2.2% |
| 2009 FY | 498.23 Billion KRW | 18.69% |
| 2009 Q2 | 504.9 Billion KRW | 4.55% |
| 2008 FY | 419.78 Billion KRW | 37.97% |
| 2008 Q4 | 419.78 Billion KRW | 15.03% |
| 2008 Q3 | 364.94 Billion KRW | 4.59% |
| 2008 Q2 | 348.91 Billion KRW | 5.68% |
| 2008 Q1 | 330.15 Billion KRW | 8.51% |
| 2007 Q4 | 304.25 Billion KRW | -4.22% |
| 2007 FY | 304.25 Billion KRW | 0.0% |
| 2007 Q2 | 391.94 Billion KRW | 2.01% |
| 2007 Q1 | 384.22 Billion KRW | 0.0% |
| 2007 Q3 | 317.67 Billion KRW | -18.95% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -225.426% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 67.041% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 26.449% |
| HANDOK Inc. | 790.33 Billion KRW | 18.385% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -278.056% |
| Yuhan Corporation | 2814.07 Billion KRW | 77.078% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 50.956% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -590.036% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 66.956% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -169.05% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -37.563% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -461.034% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -172.687% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -85.151% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -225.426% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -53.877% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -29.066% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -9.441% |
| JW Holdings Corporation | 1176.26 Billion KRW | 45.162% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -5.526% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 54.006% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -84.253% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -318.745% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -74.015% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -32.363% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -225.426% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 40.167% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 63.564% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 0.0% |
| Yuhan Corporation | 2814.07 Billion KRW | 77.078% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 26.7% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -184.659% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 35.09% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -53.617% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -37.576% |
| CKD Bio Corp. | 293.78 Billion KRW | -119.561% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -26.977% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -14.172% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -60.767% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -84.253% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 55.698% |
| Boryung Corporation | 922.36 Billion KRW | 30.067% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -45.784% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -37.563% |
| JW Lifescience Corporation | 255.83 Billion KRW | -152.129% |